A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. View (RXRX) real-time stock price, chart, news, analysis, analyst reviews and more.

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.